Parliament Approves Import of Vital ADHD Medication in Major Healthcare Policy Shift

The Maldivian Parliament has approved the importation of a critical medication used to treat children diagnosed with Attention Deficit Hyperactivity Disorder (ADHD), signaling a significant shift in the nation's healthcare and regulatory framework. The legislative change follows a government motion to amend Schedule 1 of the Drugs Act. After a thorough review by the Committee on National Security Services, the measure was passed by attending members of Parliament without dissent, legally sanctioning the drug's entry into the country. Until now, Methylphenidate—a central nervous system stimulant used to treat ADHD and narcolepsy—was strictly classified as a prohibited substance. The decision to reclassify the medication was driven by the executive branch following strategic guidance from the National Drug Control Council. The Cabinet subsequently determined that parliamentary consent was necessary to officially remove the drug from the prohibited narcotics list. Medical experts recognize Methylphenidate as a primary, first-line clinical treatment for ADHD, one of the most common developmental conditions affecting children. Research indicates that when the medication is integrated with targeted therapeutic interventions, it can substantially alleviate symptoms and improve the quality of life for young patients. Regulatory authorities have emphasized that the medication is an "essential and highly important treatment," reinforcing the clinical urgency behind the legislative update. By removing these legal barriers, the government aims to ensure that Maldivian children have access to globally recognized medical standards for managing neurodevelopmental disorders.